Abstract 332MO
Background
To compare long-term toxicity incidences, including secondary cancer (Sec.ca) with or without TBI, in Asian patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using a nationwide database.
Methods
We identified 4,554 patients receiving HSCT for leukemic disease from 2009 to 2016 using the Healthcare Bigdata system of Korea. Incidence rate ratios (IRRs) for Sec.Ca, cataracts, hypothyroidism, chronic kidney disease (CKD), myocardial infarctions (MIs), or strokes were compared, and standardized incidence ratios (SIR) of Sec.ca was also estimated.
Results
TBI was conducted on 1,409 patients (30.9%). No overall survival differences based on TBI were observed. With a median follow-up duration of 58.2 months, 143 patients were diagnosed with subsequent Sec.Ca (3.4%). Incidence rates per 1000 Person-Year (95% CI) were 6.56(4.75–8.84) and 7.23(5.89–8.80) in the TBI and no-TBI groups, respectively (p=.594). Also, the SIR (95% CI) was not significantly increased by TBI [1.32(0.86–1.94) vs. 1.39(1.08–1.77) in the no-TBI group]. In the young age group (0-19 years), SIRs were increased in both groups regardless of TBI (8.60 vs. 11.96). The IRRs (95% CI) of cataracts [1.60(1.30–1.95)], CKD [1.85(1.31–2.62)], and hypothyroidism [1.50(1.07–2.09)] were significantly increased after TBI. However, there were no significant differences in the occurrence of MI and stroke according to TBI.
Conclusions
Our results suggest that modern TBI may not additionally increase the risk of Sec.ca after allogeneic HSCT, although increased risks of other diseases were noted. Physicians should carefully consider individualized risks and benefits of TBI, with a particular focus by age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Chungnam National Universit.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Invited Discussant 333MO and 334MO
Presenter: Jason Chan Yong Sheng
Session: Mini oral session: Haematological malignancies
Resources:
Slides
Webcast
335MO - Real-world outcomes of diffuse large B cell lymphoma treated with R-CHOP(-like) therapy in an Asian multi-ethnic population
Presenter: Jason Chan Yong Sheng
Session: Mini oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
336MO - Genetic landscape and prognostic value of IRF4 alterations in diffuse large B cell lymphoma patients
Presenter: Xinrui Chen
Session: Mini oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
Invited Discussant 335MO and 336MO
Presenter: Dok Hyun Yoon
Session: Mini oral session: Haematological malignancies
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session: Haematological malignancies
Resources:
Webcast